Clinical and Economic Outcomes in Medicare Beneficiaries with Stage 3 or Stage 4 Chronic Kidney Disease and Anemia: The Role of Intravenous Iron Therapy

BACKGROUND: Anemia in patients with chronic kidney disease (CKD) is associated with increased morbidity and mortality, decreased quality of life, and substantial health care costs. Iron therapy is recommended, usually in combination with an erythropoiesis-stimulating agent (ESA), in many CKD patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Tyler, Ryan, Kellie, Schaefer, Caroline, D'Sylva, Lynell, Durden, Emily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437464/
https://www.ncbi.nlm.nih.gov/pubmed/20866165
http://dx.doi.org/10.18553/jmcp.2010.16.8.605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437464/
https://www.ncbi.nlm.nih.gov/pubmed/20866165
http://dx.doi.org/10.18553/jmcp.2010.16.8.605

Ejemplares similares